{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T04:19:11Z","timestamp":1785903551193,"version":"3.56.0"},"reference-count":95,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T00:00:00Z","timestamp":1707955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>In recent years, considerable achievements have been made in pediatric oncology with the innovation and development of antitumor drugs. However, compared to adults, children as a special group have not yet matured fully in terms of liver and kidney function. Moreover, pediatric patients are prone to more adverse drug reactions (ADRs) from the accumulation of antineoplastic drugs due to their smaller body size and larger body surface area. Chemotherapy-related ADRs have become a non-negligible factor that affects cancer remission. To date, studies on ADRs in pediatric cancer patients have emerged internationally, but few systematic summaries are available. Here, we reviewed the various systemic ADRs associated with antitumor drugs in children and adolescent patients, as well as the advances in strategies to cope with ADRs, which consisted of neurotoxicity, hematological toxicity, cardiotoxicity, ADRs of the respiratory system and gastrointestinal system and urinary system, ADRs of the skin and its adnexa, allergic reactions, and other ADRs. For clinicians and researchers, understanding the causes, symptoms, and coping strategies for ADRs caused by anticancer treatments will undoubtedly benefit more children.<\/jats:p>","DOI":"10.3389\/fphar.2024.1329220","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T05:27:12Z","timestamp":1707974832000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Anticancer therapy-induced adverse drug reactions in children and preventive and control measures"],"prefix":"10.3389","volume":"15","author":[{"given":"Hui","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penggao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weyland","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congcong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,2,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/S1470-2045(19)30339-0","article-title":"The global burden of childhood and adolescent cancer in 2017: an analysis of the Global Burden of Disease Study 2017","volume":"20","year":"2019","journal-title":"Lancet Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"114819","DOI":"10.1016\/j.biopha.2023.114819","article-title":"Cyclophosphamide enfeebles myocardial isometric contraction force via RIP1\/RIP3\/MLKL\/TRPM7-mediated necroptosis","volume":"163","author":"Abulfadl","year":"2023","journal-title":"Biomed. Pharmacother. = Biomedecine Pharmacother."},{"key":"B3","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.clml.2022.08.009","article-title":"SOHO state of the art updates and next questions | asparaginase-understanding and overcoming toxicities in adults with ALL","volume":"22","author":"Aldoss","year":"2022","journal-title":"myeloma & leukemia"},{"key":"B4","doi-asserted-by":"publisher","first-page":"777498","DOI":"10.3389\/fphar.2021.777498","article-title":"Adverse drug reactions in pediatric oncohematology: a systematic review","volume":"12","author":"Amaro-Hosey","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s10555-013-9447-3","article-title":"Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch","volume":"32","author":"Baldo","year":"2013","journal-title":"Cancer metastasis Rev."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1200\/JCO.2015.61.7613","article-title":"Toxicities and adverse drug reactions experienced during anticancer treatment: it is desirable to consider the problem within the international system of pharmacovigilance","volume":"33","author":"Baldo","year":"2015","journal-title":"J. Clin. Oncol. official J. Am. Soc. Clin. Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e30214","DOI":"10.1002\/pbc.30214","article-title":"Use of gemcitabine, oxaliplatin, and anti-CD20 therapy in children and adolescents with non-Hodgkin lymphoma unfit for intensive therapy","volume":"70","author":"Bender","year":"2023","journal-title":"Pediatr. blood cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1055\/s-2007-976172","article-title":"Adverse effects of drugs used to treat hematologic malignancies: surveillance efforts from the research on adverse drug events and reports project","volume":"33","author":"Bennett","year":"2007","journal-title":"Seminars thrombosis hemostasis"},{"key":"B9","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1002\/pbc.21132","article-title":"A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study","volume":"50","author":"Bond","year":"2008","journal-title":"Pediatr. blood cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2165\/00148581-200608030-00003","article-title":"Treatments for astrocytic tumors in children: current and emerging strategies","volume":"8","author":"Burzynski","year":"2006","journal-title":"Paediatr. drugs"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1158\/1078-0432.CCR-19-2685","article-title":"Exposure-toxicity association of cyclophosphamide and its metabolites in infants and young children with primary brain tumors: implications for dosing","volume":"26","author":"Campagne","year":"2020","journal-title":"Clin. cancer Res. official J. Am. Assoc. Cancer Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s00280-015-2933-2","article-title":"International randomized phase 2 study on the addition of docetaxel to the combination of cisplatin and 5-fluorouracil in the induction treatment for nasopharyngeal carcinoma in children and adolescents","volume":"77","author":"Casanova","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S1875-5364(23)60514-X","article-title":"Fu-Zheng-Yi-Liu formula inhibits the stem cells and metastasis of prostate cancer via tumor-associated macrophages\/C-C motif chemokine ligand 5 pathway in tumor microenvironment","volume":"21","author":"Chen","year":"2023","journal-title":"Chin. J. Nat. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.2147\/IJN.S231407","article-title":"Improvement of paclitaxel-associated adverse reactions (ADRs) via the use of nano-based drug delivery systems: a systematic review and Network meta-analysis","volume":"15","author":"Chou","year":"2020","journal-title":"Int. J. nanomedicine"},{"key":"B15","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1634\/theoncologist.2016-0319","article-title":"A systematic review of strategies to prevent cisplatin-induced nephrotoxicity","volume":"22","author":"Crona","year":"2017","journal-title":"Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/S2352-4642(22)00239-5","article-title":"Primary cardioprotection with dexrazoxane in patients with childhood cancer who are expected to receive anthracyclines: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group","volume":"6","author":"De Baat","year":"2022","journal-title":"Lancet Child Adolesc. health"},{"key":"B17","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1166\/jbn.2018.2530","article-title":"Vincristine-loaded and sgc8-modified liposome as a potential targeted drug delivery system for treating acute lymphoblastic leukemia","volume":"14","author":"Duan","year":"2018","journal-title":"J. Biomed. Nanotechnol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"3771","DOI":"10.1200\/JCO.2013.53.1590","article-title":"Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group","volume":"32","author":"Flaherty","year":"2014","journal-title":"J. Clin. Oncol. official J. Am. Soc. Clin. Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1093\/annonc\/mdv616","article-title":"Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis","volume":"27","author":"Fleury","year":"2016","journal-title":"Ann. Oncol. official J. Eur. Soc. Med. Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1159\/000342232","article-title":"Measurement of red cell lifespan and aging","volume":"39","author":"Franco","year":"2012","journal-title":"Transfus. Med. hemotherapy offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie"},{"key":"B21","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S2352-4642(19)30336-0","article-title":"Prevention of cisplatin-induced ototoxicity in children and adolescents with cancer: a clinical practice guideline","volume":"4","author":"Freyer","year":"2020","journal-title":"Lancet Child Adolesc. health"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.3389\/fphar.2018.01394","article-title":"Multi-component herbal products in the prevention and treatment of chemotherapy-associated toxicity and side effects: a review on experimental and clinical evidences","volume":"9","author":"Fu","year":"2018","journal-title":"Front. Pharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1021\/np1008152","article-title":"Comparative analysis of the biosynthetic gene clusters and pathways for three structurally related antitumor antibiotics: bleomycin, tallysomycin, and zorbamycin","volume":"74","author":"Galm","year":"2011","journal-title":"J. Nat. Prod."},{"key":"B24","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.jaip.2017.03.015","article-title":"Immediate hypersensitivity reaction to chemotherapeutic agents","volume":"5","author":"Giavina-Bianchi","year":"2017","journal-title":"J. allergy Clin. Immunol. Pract."},{"key":"B25","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1053\/j.seminoncol.2005.11.007","article-title":"Extravasation of chemotherapeutic agents: prevention and treatment","volume":"33","author":"Goolsby","year":"2006","journal-title":"Seminars Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1093\/jnci\/djaa007","article-title":"International trends in the incidence of cancer among adolescents and young adults","volume":"112","author":"Gupta","year":"","journal-title":"J. Natl. Cancer Inst."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1200\/JCO.19.03024","article-title":"Impact of asparaginase discontinuation on outcome in childhood acute lymphoblastic leukemia: a report from the children's oncology group","volume":"38","author":"Gupta","year":"","journal-title":"J. Clin. Oncol. official J. Am. Soc. Clin. Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/ana.25502","article-title":"Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy","volume":"86","author":"Gust","year":"2019","journal-title":"Ann. neurology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/S12094-010-0474-z","article-title":"Chemotherapy-induced peripheral neuropathy: clinical features, diagnosis, prevention and treatment strategies","volume":"12","author":"Guti\u00e9RREZ-Guti\u00e9RREZ","year":"2010","journal-title":"Clin. Transl. Oncol. official Publ. Fed. Span. Oncol. Soc. Natl. Cancer Inst. Mexico"},{"key":"B30","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2169\/internalmedicine.53.1342","article-title":"Incidence of malignancies in patients with IgG4-related disease","volume":"53","author":"Hirano","year":"2014","journal-title":"Intern. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s40168-019-0679-5","article-title":"Chemotherapy-induced oral mucositis is associated with detrimental bacterial dysbiosis","volume":"7","author":"Hong","year":"2019","journal-title":"Microbiome"},{"key":"B32","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jaip.2013.11.007","article-title":"Indications, protocols, and outcomes of drug desensitizations for chemotherapy and monoclonal antibodies in adults and children","volume":"2","author":"Hong","year":"2014","journal-title":"J. allergy Clin. Immunol. Pract."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.4103\/0366-6999.233950","article-title":"Detection of subclinical anthracyclines' cardiotoxicity in children with solid tumor","volume":"131","author":"Hu","year":"2018","journal-title":"Chin. Med. J."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1002\/ijc.31269","article-title":"Clinical evidence of prevention strategies for capecitabine-induced hand-foot syndrome","volume":"142","author":"Huang","year":"2018","journal-title":"Int. J. cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"109402","DOI":"10.1016\/j.cbi.2021.109402","article-title":"Resveratrol protects against cisplatin-induced ovarian and uterine toxicity in female rats by attenuating oxidative stress, inflammation and apoptosis","volume":"338","author":"Ibrahim","year":"2021","journal-title":"Chemico-biological Interact."},{"key":"B36","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2174\/1574892811666161026111721","article-title":"Melissa of cinalis and vitamin E as the potential therapeutic candidates for reproductive toxicity caused by anti-cancer drug, cisplatin, in male rats","volume":"12","author":"Iman","year":"2017","journal-title":"Recent Pat. anti-cancer drug Discov."},{"key":"B37","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1046\/j.0306-5251.2001.01407.x","article-title":"Incidence of adverse drug reactions in paediatric in\/out-patients: a systematic review and meta-analysis of prospective studies","volume":"52","author":"Impicciatore","year":"2001","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"516","DOI":"10.5603\/GP.2016.0036","article-title":"Chemotherapy-induced peripheral neuropathy - diagnosis, evolution and treatment","volume":"87","author":"I\u017cycki","year":"2016","journal-title":"Ginekol. Pol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"807171","DOI":"10.3389\/fonc.2021.807171","article-title":"Suspected adverse drug reactions in pediatric cancer patients in China: an analysis of henan Province spontaneous reporting system database","volume":"11","author":"Jiao","year":"2021","journal-title":"Front. Oncol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.radonc.2021.06.003","article-title":"Optimal cumulative cisplatin dose during concurrent chemoradiotherapy among children and adolescents with locoregionally advanced nasopharyngeal carcinoma: a real-world data study","volume":"161","author":"Jin","year":"2021","journal-title":"J. Eur. Soc. Ther. Radiology Oncol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"5134","DOI":"10.2174\/1381612826666200701151403","article-title":"Gold nanoparticles- boon in cancer theranostics","volume":"26","author":"Jindal","year":"2020","journal-title":"Curr. Pharm. Des."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1093\/neuonc\/nox147","article-title":"Intracystic interferon-alpha in pediatric craniopharyngioma patients-reply","volume":"19","author":"John-Paul","year":"2017","journal-title":"Neuro-oncology"},{"key":"B43","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1097\/01.ju.0000130653.74548.d6","article-title":"Adverse reactions of nitrofurantoin, trimethoprim and sulfamethoxazole in children","volume":"172","author":"Karpman","year":"2004","journal-title":"J. urology"},{"key":"B44","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human chimeric antigen receptor macrophages for cancer immunotherapy","volume":"38","author":"Klichinsky","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.3390\/ijms22031362","article-title":"Cancer-targeted controlled delivery of chemotherapeutic anthracycline derivatives using apoferritin nanocage carriers","volume":"22","author":"Kurz\u0105tkowska","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B46","doi-asserted-by":"publisher","first-page":"e968","DOI":"10.1634\/theoncologist.2018-0476","article-title":"Adverse drug reactions in an oncological population: prevalence, predictability, and preventability","volume":"24","author":"Lavan","year":"2019","journal-title":"Oncol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/S1875-5364(22)60193-6","article-title":"Potential of ginsenoside Rh2 and its derivatives as anti-cancer agents","volume":"20","author":"Li","year":"2022","journal-title":"Chin. J. Nat. Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13045-020-01014-w","article-title":"NK cell-based cancer immunotherapy: from basic biology to clinical development","volume":"14","author":"Liu","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S1875-5364(23)60502-3","article-title":"Palmitic acid reduces the methylation of the FOXO1 promoter to suppress the development of diffuse large B-cell lymphoma via modulating the miR-429\/DNMT3A axis","volume":"21","author":"Li","year":"2023","journal-title":"Chin. J. Nat. Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"6600","DOI":"10.1172\/JCI140797","article-title":"Pharmacogenomics of intracellular methotrexate polyglutamates in patients' leukemia cells in vivo","volume":"130","author":"Lopez-Lopez","year":"2020","journal-title":"J. Clin. investigation"},{"key":"B51","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/ijc.28363","article-title":"Allergies, atopy, immune-related factors and childhood rhabdomyosarcoma: a report from the Children's Oncology Group","volume":"134","author":"Lupo","year":"2014","journal-title":"Int. J. cancer"},{"key":"B52","doi-asserted-by":"publisher","first-page":"7840","DOI":"10.12998\/wjcc.v9.i26.7840","article-title":"Extravasation of chemotherapeutic drug from an implantable intravenous infusion port in a child: a case report","volume":"9","author":"Lv","year":"2021","journal-title":"World J. Clin. cases"},{"key":"B53","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/MOP.0000000000000173","article-title":"New developments in pediatric venous thromboembolism and anticoagulation, including the target-specific oral anticoagulants","volume":"27","author":"Lyle","year":"2015","journal-title":"Curr. Opin. Pediatr."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1007\/s00415-018-8890-z","article-title":"Severe neurologic complications of immune checkpoint inhibitors: a single-center review","volume":"265","author":"Mancone","year":"2018","journal-title":"J. neurology"},{"key":"B55","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1016\/j.bmcl.2018.06.044","article-title":"Vinca alkaloids and analogues as anti-cancer agents: looking back, peering ahead","volume":"28","author":"Martino","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B56","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1097\/MPG.0000000000003334","article-title":"Clinical characteristics and short-term outcomes of children with asparaginase-associated pancreatitis","volume":"74","author":"Mauney","year":"2022","journal-title":"J. Pediatr. gastroenterology Nutr."},{"key":"B57","doi-asserted-by":"publisher","first-page":"e2036321","DOI":"10.1001\/jamanetworkopen.2020.36321","article-title":"Association of rituximab use with adverse events in children, adolescents, and young adults","volume":"4","author":"Mcatee","year":"2021","journal-title":"JAMA Netw. open"},{"key":"B58","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ejca.2020.02.010","article-title":"The 2016-2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study","volume":"130","author":"Michot","year":"2020","journal-title":"Eur. J. cancer (Oxford, Engl. 1990)"},{"key":"B59","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1200\/JCO.20.00203","article-title":"Irinotecan, temozolomide, and dinutuximab with GM-CSF in children with refractory or relapsed neuroblastoma: a report from the children's oncology group","volume":"38","author":"Mody","year":"2020","journal-title":"J. Clin. Oncol. official J. Am. Soc. Clin. Oncol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"5376476","DOI":"10.1155\/2018\/5376476","article-title":"Anticancer drugs induced severe adverse cutaneous drug reactions: an updated review on the risks associated with anticancer targeted therapy or immunotherapies","volume":"2018","author":"Ng","year":"2018","journal-title":"J. Immunol. Res."},{"key":"B62","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1517\/14740338.2013.828034","article-title":"Vascular endothelial growth factor inhibitors and cognitive impairment: evidence and controversies","volume":"13","author":"Ng","year":"2014","journal-title":"Expert Opin. drug Saf."},{"key":"B63","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","article-title":"CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy","volume":"41","author":"Pan","year":"2022","journal-title":"J. Exp. Clin. cancer Res. CR"},{"key":"B64","doi-asserted-by":"publisher","first-page":"340","DOI":"10.5530\/jyp.2018.10.75","article-title":"Chemotherapy-induced adverse drug reactions in pediatric oncology","volume":"10","author":"Pawar","year":"2018","journal-title":"J. Young Pharm."},{"key":"B65","doi-asserted-by":"publisher","first-page":"Cd007786","DOI":"10.1002\/14651858.CD007786.pub2","article-title":"Antiemetic medication for prevention and treatment of chemotherapy-induced nausea and vomiting in childhood","volume":"2","author":"Phillips","year":"2016","journal-title":"Cochrane database Syst. Rev."},{"key":"B66","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41571-021-00474-4","article-title":"Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer","volume":"18","author":"Ragoonanan","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.3390\/antiox10121919","article-title":"Oxidative stress and inflammation caused by cisplatin ototoxicity","volume":"10","author":"Ramkumar","year":"2021","journal-title":"Antioxidants Basel, Switz."},{"key":"B68","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s43440-020-00109-y","article-title":"Chemotherapy-induced peripheral neuropathy: part 1-current state of knowledge and perspectives for pharmacotherapy","volume":"72","author":"Sa\u0142at","year":"","journal-title":"Pharmacol. Rep. P. R."},{"key":"B69","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1007\/s43440-020-00106-1","article-title":"Chemotherapy-induced peripheral neuropathy-part 2: focus on the prevention of oxaliplatin-induced neurotoxicity","volume":"72","author":"Sa\u0142at","year":"","journal-title":"Pharmacol. Rep. P. R."},{"key":"B70","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","article-title":"Rituximab in B-cell hematologic malignancies: a review of 20 Years of clinical experience","volume":"34","author":"Salles","year":"2017","journal-title":"Adv. Ther."},{"key":"B71","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ctrv.2003.07.003","article-title":"Cardiotoxicity of cytotoxic drugs","volume":"30","author":"Schimmel","year":"2004","journal-title":"Cancer Treat. Rev."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1200\/JCO.19.03279","article-title":"CD4\/CD8 T-Cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial","volume":"38","author":"Shah","year":"2020","journal-title":"J. Clin. Oncol. official J. Am. Soc. Clin. Oncol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1093\/neuonc\/noac034","article-title":"Neurotoxicity following CD19\/CD28\u03b6 CAR T-cells in children and young adults with B-cell malignancies","volume":"24","author":"Shalabi","year":"2022","journal-title":"Neuro-oncology"},{"key":"B74","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics","volume":"71","author":"Siegel","year":"2021","journal-title":"CA a cancer J. Clin."},{"key":"B75","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1200\/JCO.1993.11.1.173","article-title":"Ifosfamide, mesna, and nephrotoxicity in children","volume":"11","author":"Skinner","year":"1993","journal-title":"J. Clin. Oncol. official J. Am. Soc. Clin. Oncol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1378\/chest.99.3.557","article-title":"Cardiotoxicity of interferon. A review of 44 cases","volume":"99","author":"Sonnenblick","year":"1991","journal-title":"Chest"},{"key":"B77","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/S1470-2045(17)30186-9","article-title":"International incidence of childhood cancer, 2001-10: a population-based registry study","volume":"18","author":"Steliarova-Foucher","year":"2017","journal-title":"Lancet Oncol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1182\/blood-2018-10-881961","article-title":"A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403","volume":"133","author":"Stock","year":"2019","journal-title":"Blood"},{"key":"B79","doi-asserted-by":"publisher","first-page":"103607","DOI":"10.1016\/j.critrevonc.2022.103607","article-title":"Diagnosis and treatment of therapy-related acute myeloid leukemia","volume":"171","author":"Strickland","year":"2022","journal-title":"Crit. Rev. oncology\/hematology"},{"key":"B80","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.therap.2021.12.006","article-title":"Dermatological adverse drug reactions of anticancer drugs: international data of pharmacovigilance: VigiBase\u00ae","volume":"77","author":"Strumia","year":"2022","journal-title":"Therapie"},{"key":"B81","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1039\/b907567d","article-title":"Inhibition of transcription by platinum antitumor compounds","volume":"1","author":"Todd","year":"2009","journal-title":"Metallomics Integr. biometal Sci."},{"key":"B82","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1002\/cpt.1311","article-title":"Pediatric anthracycline-induced cardiotoxicity: mechanisms, pharmacogenomics, and pluripotent stem-cell modeling","volume":"105","author":"Tripaydonis","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"B83","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.anai.2020.01.010","article-title":"Evaluation of hypersensitivity reactions to cancer chemotherapeutic agents in pediatric patients","volume":"124","author":"Turgay","year":"2020","journal-title":"Ann. allergy, asthma & Immunol. official Publ. Am. Coll. Allergy, Asthma, & Immunol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1002\/pbc.24244","article-title":"Phase 2 trial of pemetrexed in children and adolescents with refractory solid tumors: a Children's Oncology Group study","volume":"60","author":"Warwick","year":"2013","journal-title":"Pediatr. blood cancer"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1093\/neuonc\/nov181","article-title":"Phase I study of 5-fluorouracil in children and young adults with recurrent ependymoma","volume":"17","author":"Wright","year":"2015","journal-title":"Neuro-oncology"},{"key":"B86","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1002\/pbc.21721","article-title":"Octreotide therapy in asparaginase-associated pancreatitis in childhood acute lymphoblastic leukemia","volume":"51","author":"Wu","year":"2008","journal-title":"Pediatr. blood cancer"},{"key":"B87","doi-asserted-by":"publisher","first-page":"102975","DOI":"10.1016\/j.ebiom.2020.102975","article-title":"CAR-NK cells: a promising cellular immunotherapy for cancer","volume":"59","author":"Xie","year":"2020","journal-title":"EBioMedicine"},{"key":"B88","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41408-022-00694-6","article-title":"Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study","volume":"12","author":"Yang","year":"2022","journal-title":"Blood cancer J."},{"key":"B89","doi-asserted-by":"publisher","first-page":"106416","DOI":"10.1016\/j.ejps.2023.106416","article-title":"External evaluation and systematic review of population pharmacokinetic models for high-dose methotrexate in cancer patients","volume":"186","author":"Yang","year":"2023","journal-title":"Eur. J. Pharm. Sci. official J. Eur. Fed. Pharm. Sci."},{"key":"B90","doi-asserted-by":"publisher","first-page":"100255","DOI":"10.1016\/j.esmoop.2021.100255","article-title":"Worldwide cancer statistics of adolescents and young adults in 2019: a systematic analysis of the Global Burden of Disease Study 2019","volume":"6","author":"You","year":"2021","journal-title":"ESMO open"},{"key":"B91","doi-asserted-by":"publisher","first-page":"509","DOI":"10.2174\/1568009616666151130213910","article-title":"Targeted delivery of bleomycin: a comprehensive anticancer review","volume":"16","author":"Yu","year":"2016","journal-title":"Curr. cancer drug targets"},{"key":"B92","doi-asserted-by":"publisher","first-page":"112269","DOI":"10.1016\/j.jep.2019.112269","article-title":"Protective effect of Liuwei Dihuang Pill on cisplatin-induced reproductive toxicity and genotoxicity in male mice","volume":"247","author":"Zhang","year":"2020","journal-title":"J. Ethnopharmacol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40364-022-00364-6","article-title":"CAR-NK cells for cancer immunotherapy: from bench to bedside","volume":"10","author":"Zhang","year":"2022","journal-title":"Biomark. Res."},{"key":"B94","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.canlet.2015.04.021","article-title":"Incidence, mortality and survival of childhood cancer in China during 2000-2010 period: a population-based study","volume":"363","author":"Zheng","year":"2015","journal-title":"Cancer Lett."},{"key":"B95","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1002\/cam4.2889","article-title":"Septicemia after chemotherapy for childhood acute lymphoblastic leukemia in China: a multicenter study CCCG-ALL-2015","volume":"9","author":"Zhu","year":"2020","journal-title":"Cancer Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1329220\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T05:27:29Z","timestamp":1707974849000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1329220\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,15]]},"references-count":95,"alternative-id":["10.3389\/fphar.2024.1329220"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1329220","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,15]]},"article-number":"1329220"}}